NielsenP.K., Feldt-RasmussenU., OlgaardK.A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells.Nephrol Dial Transplant.1996; 9: 1762–9.
2.
ShojiS., NishizawaY., TabataT., EmotoM., MoritaA., GotoH.Influence of serum phosphate on the efficacy of oral 1,25 dihydroxyvitamin D3 pulse therapy.Miner Electrolyte Metab.1995; 21: 223–8.
3.
GoldsmithD.J., CovicA., SambrookP.A., AckrillP.Vascular calcification in long-term haemodialysis patients in a single unit: A retrospective analysis.Nephron.1997; 77: 37–43.
4.
BlockG.A., Hulbert-ShearonT.E., LevinN.W., PortF.K.Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study.Am J Kidney Dis.1998; 31: 607–17.
5.
MartisL., SerkesK.D., NolphK.D.Calcium carbonate as a phosphate binder: Is there a need to adjust peritoneal dialysate calcium concentrations for patients using CaCO3?PeTit Dial Int.1989; 9: 325–8.
6.
HutchisonA.J., BoultonH.F., GokalR.Low-calcium dialysis fluid and oral calcium carbonate in CAPD: A method of controlling hyperphosphataemia whilst minimising aluminium exposure and hypercalcaemia.Nephrol Dial Transplant.1992; 7: 1219–25.
7.
CunninghamJ., BeerJ., ColdwellR.D., NoonanK., SawyerN., MakinH.L.Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol.Nephrol Dial Transplant.1992; 7: 63–8.
8.
AckrillP., DayJ.P., AhmedR.Aluminum and iron overload in chronic dialysis.Kidney Int.1988; 24(Suppl 1); S163–7.
9.
McGaryT.J., NolphK.D., MooreH.L., KartinosN.J.Polycation as an alternative osmotic agent and phosphate binder in peritoneal dialysis.Uremia Invest.1984–5; 8: 79–84.
10.
SpenglerK., FollmannH., BoosK.S., SeidelD., MaywaldF.Characterisation and extracorporeal application of a new phosphate-binding agent.Eur J Clin Chem Clin Biochem.1994; 32: 733–9.
11.
PasslickJ., WilhelmM., BuschT., GrabenseeB., OhnesorgeF.K.Calcium alginate, an aluminum free phosphate binder, in patients on CAPD.Clin Nephrol.1989; 32: 96–100.
12.
MoriniereP., MaurouardC., BoudailliezB., WesteelP.F., AchardJ.M., BoitteF.Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder.Nephron.1992; 60: 154–63.
13.
ParsonsV., BaldwinD., MonizC., MarsdenJ., BallE., RifkinI.Successful control of hyperparathyroidism in patients on CAPD using magnesium carbonate and calcium carbonate as phosphate binders.Nephron.1993; 63: 379–83.
MaciaM., CoronelF., NavarroJ.F., GallegoE., HerreroJ.A., MendezM.L.Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD.Clin Nephrol.1997; 48: 181–4.
17.
BroS., RasmussenR.A., HandbergJ., OlgaardK., Feldt-RasmussenB.Randomized crossover study comparing the phosphate binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis.Am J Kidney Dis.1998; 31: 257–62.
18.
KurodaS., KomoriM., NagamatsuK., NinomiyaR., MaejimaK., HasegawaK.Effect of iron as a new type of phosphate binder in hemodialysis patients.Nippon Jinzo Gakkai Shi.1995; 37: 468–73.
19.
GraffL., BurnelD.Reduction of dietary phosphorus absorption by oral phosphorus binders.Res Commun Mol Pathol Pharmacol.1995; 90: 389–401.
20.
ChertowG.M., BurkeS.K., LazarusJ.M., StenzelK.H., WomboltD., GoldbergD.Poly[allylamine hydrochloride] (RenaGel): A noncalcaemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.Am J Kidney Dis.1997; 29: 66–71.
21.
GraffL., BurnelD.A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption.Res Commun Mol Pathol Pharmacol.1995; 90: 373–88.
DewberryK., FoxJ.S., StewartJ., MurrayJ.R., HutchisonA.J.Lanthanum carbonate: A novel non-calcium containing phosphate binder [Abstract].J Am Soc Nephrol.1997; 8: A2610.
24.
GokalR., RamosJ., EllisH.A., ParkinsonI., SweetmanV., DewarJ.Histological renal osteodystrophy, and 25-hydroxycholecalciferol and aluminium levels in patients on CAPD.Kidney Int.1983; 23: 15–21.
SchaeferK., UmlaufE., von-HerrathD.Reduced risk of hypercalcaemia for hemodialysis patients by administering calcitriol at night.Am J Kidney Dis.1992; 19: 460–4.
27.
MartinK.J., BallalH.S., DomotoD.T., BlalockS., WeindelM.Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on CAPD: Preliminary observations.Am J Kidney Dis.1992; 19: 540–5.
28.
JoffeP., CintinC., LadefogedS.D., RasmussenS.N.Pharmacokinetics of 1-alfa-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis.Clin Nephrol.1994; 41: 364–9.
29.
CantleyL.K., RusselJ., LettieriD., SherwoodS.M.1,25-dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture.Endocrinology.1985; 117: 2114–19.
30.
ScanzianiR., DozioB., BonforteG., SurianM.Effects of calcitriol pulse therapy per os in CAPD patients. In: KhannaR., ed. Advances in Peritoneal Dialysis.Toronto: Peritoneal Dialysis Publications, 1994; 10: 270–4.
31.
BechtelU., MuckeC., FeuchtH.E., SchifflH., SitterT., HeldE.Limitations of pulse oral calcitriol therapy in CAPD.Am J Kidney Dis.1995; 25: 291–6.
32.
RomaniniD., GazoA., BellazziR., VincenziA., NaiM., SantagostinoM.Long term effect of oral calcitriol single weekly pulse in CAPD and HD. In: KhannaR., ed. Advances in Peritoneal Dialysis.Toronto: Peritoneal Dialysis Publications, 1994; 10: 267–9.
33.
PanichiV., AndreiniB., De PietroS., MiglioriM., TaccolaD., GiovanniniL.Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure.Clin Nephrol.1998; 49: 245–50.
34.
FinchJ.L., BrownA.J., KuboderaN., NishiiY., SlatopolskyE.Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism.Kidney Int.1993; 43: 561–6.
35.
NemethE.F., BennettS.A.Tricking the parathyroid gland with novel calcimimetic agents.Nephrol Dial Transplant.1998; 13: 1923–5.
